LENVATOL CAP 4 MG

About

Lenvatinib is a multi-kinase inhibitor used in the treatment of various advanced cancers, including differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma. It works by selectively inhibiting the kinase activities of vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, and FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. By targeting these multiple receptor tyrosine kinases, lenvatinib effectively inhibits tumor growth, angiogenesis (formation of new blood vessels that feed the tumor), and lymphangiogenesis. This comprehensive inhibition of key signaling pathways involved in cancer progression makes lenvatinib a powerful agent for patients with advanced or metastatic disease who have limited treatment options.

Uses

• Differentiated Thyroid Cancer (DTC)
• Hepatocellular Carcinoma (HCC)
• Renal Cell Carcinoma (RCC)
• Endometrial Carcinoma (in combination)

Directions For Use

Take orally once daily, with or without food, at approximately the same time each day. Swallow capsules whole.

Benefits

• Effective against multiple advanced cancers.
• Inhibits tumor growth and angiogenesis.
• Improves progression-free survival.
• Convenient oral administration.
• Targets multiple key signaling pathways.
• Offers a treatment option for difficult-to-treat cancers.

Side Effects

• Hypertension (high blood pressure)
• Fatigue
• Diarrhea
• Decreased appetite
• Weight loss
• Nausea
• Vomiting
• Proteinuria (protein in urine)
• Palmar-plantar erythrodysesthesia (hand-foot syndrome)
• Hypothyroidism
• Hemorrhage
• Arterial thromboembolic events

Safety Measures

• Alcohol - Avoid or limit alcohol due to potential for increased liver toxicity and exacerbation of side effects.
• Pregnancy - Category D; can cause fetal harm. Avoid during pregnancy; effective contraception is required.
• Breastfeeding - Not recommended; lenvatinib is likely excreted in breast milk and can harm the infant.
• Liver - Use with caution; dose adjustment may be necessary in patients with severe hepatic impairment.
• Kidney - Use with caution; dose adjustment may be necessary in patients with severe renal impairment.
• Lung - Monitor for pulmonary embolism, interstitial lung disease, or pneumonitis, though rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.